secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2024-07-03T23:59:59+00:00
Accession:  0001213900-24-058821
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus 2023 revenue up 61% to $29.6M, net loss narrows to $3.7M
---------------------------------------------------------------

- Net revenue $29.6M (vs $18.4M in 2022); operating income $3.5M vs loss $6.6M.
- Net loss $3.7M ($0.07/sh) vs $10.6M ($0.21/sh); cash $2.5M at Dec 31, 2023.
- MENA region and U.S. sales drove growth; disposed of Japanese JV equity interest.
- Inventory shortage impacted Q4 2023 sales; backlog ~$4.6M as of May 24, 2024; now resolved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390024058821/0001213900-24-058821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390024058821/ea0207151-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-058821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer